These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32616873)

  • 21. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
    Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
    Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic alterations in ovarian endometriosis and subsequently diagnosed ovarian carcinoma.
    Linder A; Westbom-Fremer S; Mateoiu C; Olsson Widjaja A; Österlund T; Veerla S; Ståhlberg A; Ulfenborg B; Hedenfalk I; Sundfeldt K
    Hum Reprod; 2024 May; 39(5):1141-1154. PubMed ID: 38459814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences.
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Caniego-Casas T; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; García Á; Ibarra J; Hakim S; Guarch R; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 May; 44(5):649-656. PubMed ID: 32294063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancer.
    Er TK; Su YF; Wu CC; Chen CC; Wang J; Hsieh TH; Herreros-Villanueva M; Chen WT; Chen YT; Liu TC; Chen HS; Tsai EM
    J Mol Med (Berl); 2016 Jul; 94(7):835-47. PubMed ID: 26920370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
    Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
    J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.
    Ogasawara A; Hihara T; Shintani D; Yabuno A; Ikeda Y; Tai K; Fujiwara K; Watanabe K; Hasegawa K
    Cancer Res Treat; 2020 Oct; 52(4):1219-1228. PubMed ID: 32599986
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genomic profiling of malignant phyllodes tumors reveals aberrations in FGFR1 and PI-3 kinase/RAS signaling pathways and provides insights into intratumoral heterogeneity.
    Liu SY; Joseph NM; Ravindranathan A; Stohr BA; Greenland NY; Vohra P; Hosfield E; Yeh I; Talevich E; Onodera C; Van Ziffle JA; Grenert JP; Bastian BC; Chen YY; Krings G
    Mod Pathol; 2016 Sep; 29(9):1012-27. PubMed ID: 27255162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
    Sadlecki P; Antosik P; Grzanka D; Grabiec M; Walentowicz-Sadlecka M
    Tumour Biol; 2017 Oct; 39(10):1010428317733984. PubMed ID: 28992761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of MR imaging findings and quantitative values in the differentiation of seromucinous borderline tumour from endometriosis-related malignant ovarian tumour.
    Kurata Y; Kido A; Moribata Y; Kameyama K; Himoto Y; Minamiguchi S; Konishi I; Togashi K
    Eur Radiol; 2017 Apr; 27(4):1695-1703. PubMed ID: 27553934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
    Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
    J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-grade serous carcinomas of the ovary contain very few point mutations.
    Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
    J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S; Duarte M; Albuquerque C; da Silva JP; Fonseca R; Roque R; Dias Pereira A; Chaves P; Cravo M
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
    Murakami K; Kanto A; Sakai K; Miyagawa C; Takaya H; Nakai H; Kotani Y; Nishio K; Matsumura N
    Mod Pathol; 2021 Nov; 34(11):2071-2079. PubMed ID: 34172890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.
    Zannoni GF; Santoro A; Angelico G; Spadola S; Arciuolo D; Valente M; Inzani F; Pettinato A; Vatrano S; Fanfani F; Scambia G; Fraggetta F
    Hum Pathol; 2019 Oct; 92():10-17. PubMed ID: 31269413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.